MCID: NSP003
MIFTS: 46

Nasopharyngeal Disease

Categories: Respiratory diseases

Aliases & Classifications for Nasopharyngeal Disease

MalaCards integrated aliases for Nasopharyngeal Disease:

Name: Nasopharyngeal Disease 12 15
Nasopharyngeal Diseases 56 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:9561
MeSH 45 D009302
NCIt 51 C35723
UMLS 74 C0027438

Summaries for Nasopharyngeal Disease

MalaCards based summary : Nasopharyngeal Disease, also known as nasopharyngeal diseases, is related to nasopharyngitis and rare adenocarcinoma of the breast. An important gene associated with Nasopharyngeal Disease is PSMB9 (Proteasome Subunit Beta 9), and among its related pathways/superpathways are fMLP Pathway and Human cytomegalovirus infection. The drugs Erythromycin and Nimotuzumab have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and nk cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Nasopharyngeal Disease

Diseases related to Nasopharyngeal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
# Related Disease Score Top Affiliating Genes
1 nasopharyngitis 11.1
2 rare adenocarcinoma of the breast 10.5 AKT1 TP53
3 bartholin's duct cyst 10.5 SMUG1 TP53
4 breast papillomatosis 10.5 CCND1 CDKN2A
5 cerebral convexity meningioma 10.5 CDH1 TP53
6 short-rib thoracic dysplasia 4 with or without polydactyly 10.4 CASP3 TP53
7 bile duct adenocarcinoma 10.4 AKT1 CDH1 TP53
8 malignant spiradenoma 10.4 SMUG1 TP53
9 anal squamous cell carcinoma 10.4 AKT1 CDKN2A TP53
10 ovarian cancer 1 10.4 AKT1 CDH1 TP53
11 pharynx squamous cell carcinoma 10.4 AKT1 CASP3 SMUG1
12 cellular ependymoma 10.4 SMUG1 TP53
13 malignant ovarian surface epithelial-stromal neoplasm 10.4 AKT1 CDH1 TP53
14 ovary epithelial cancer 10.4 AKT1 CDH1 TP53
15 protoplasmic astrocytoma 10.4 SMUG1 TP53
16 oral leukoplakia 10.4 CCND1 CDKN2A TP53
17 tonsil squamous cell carcinoma 10.4 CCND1 CDKN2A
18 tongue disease 10.4 CDH1 CDKN2A TP53
19 tonsil cancer 10.4 CDH1 CDKN2A TP53
20 verrucous carcinoma 10.4 CCND1 CDKN2A TP53
21 estrogen-receptor positive breast cancer 10.4 AKT1 CCND1 TP53
22 epstein-barr virus-associated gastric carcinoma 10.4 CDH1 CDKN2A PSMB9
23 connective tissue cancer 10.4 AKT1 SMUG1 TP53
24 colloid adenoma 10.4 SMUG1 TP53
25 pleural cancer 10.4 AKT1 CDKN2A SMUG1
26 in situ carcinoma 10.4 CDH1 CDKN2A TP53
27 bladder squamous cell carcinoma 10.4 CDKN2A TP53
28 inverted papilloma 10.4 CCND1 CDKN2A TP53
29 penile cancer 10.4 CCND1 CDKN2A TP53
30 cholecystitis 10.4 CDH1 CDKN2A TP53
31 cervical squamous cell carcinoma 10.4 CDH1 CDKN2A TP53
32 megaesophagus 10.4 CDKN2A MYC TP53
33 suppressor of tumorigenicity 3 10.4 CDKN2A MYC TP53
34 anaplastic thyroid cancer 10.4 CASP3 CDH1 TP53
35 breast ductal carcinoma 10.4 CCND1 CDH1 TP53
36 pleomorphic adenoma carcinoma 10.4 BPIFB1 TP53
37 ductal carcinoma in situ 10.4 AKT1 CCND1 CDH1 TP53
38 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
39 endometrial adenocarcinoma 10.4 AKT1 CDKN2A TP53
40 skin melanoma 10.4 CASP3 CDKN2A TP53
41 pre-malignant neoplasm 10.4 CCND1 CDH1 CDKN2A TP53
42 laryngeal disease 10.4 CCND1 CDH1 CDKN2A TP53
43 laryngeal squamous cell carcinoma 10.3 CCND1 CDH1 CDKN2A TP53
44 bowenoid papulosis 10.3 CCND1 CDKN2A
45 supratentorial cancer 10.3 AKT1 CASP3 CDKN2A TP53
46 esophageal disease 10.3 CCND1 CDKN2A SMUG1 TP53
47 cerebrum cancer 10.3 AKT1 CASP3 CDKN2A TP53
48 upper respiratory tract disease 10.3 CDKN2A TMEM8B TP53
49 gallbladder cancer 10.3 AKT1 CDH1 CDKN2A TP53
50 suppression of tumorigenicity 12 10.3 AKT1 CDH1 TP53

Graphical network of the top 20 diseases related to Nasopharyngeal Disease:



Diseases related to Nasopharyngeal Disease

Symptoms & Phenotypes for Nasopharyngeal Disease

GenomeRNAi Phenotypes related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.96 AKT1 CDH1 CDKN2A MAPK9 MYC
2 Decreased viability GR00221-A-2 9.96 AKT1 MAPK9
3 Decreased viability GR00221-A-3 9.96 AKT1 CDKN2A MAPK9 MYC
4 Decreased viability GR00221-A-4 9.96 AKT1 CDKN2A
5 Decreased viability GR00301-A 9.96 CDH1 MAPK9
6 Decreased viability GR00402-S-2 9.96 AKT1 CDH1 CDKN2A MAPK9 MYC
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 AKT1 CASP3 CDKN2A PSMB9 TP53
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 AKT1 CASP3 CCND1 CDKN2A MYC PSMB9

MGI Mouse Phenotypes related to Nasopharyngeal Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 AKT1 BPIFB1 BRD7 CASP3 CCND1 CDH1
2 immune system MP:0005387 10.11 AKT1 BPIFA1 CASP3 CCND1 CDH1 CDKN2A
3 mortality/aging MP:0010768 10.07 AKT1 B4GALT5 BPIFA1 BRD7 CASP3 CCND1
4 integument MP:0010771 9.97 AKT1 BRD7 CASP3 CCND1 CDH1 CDKN2A
5 digestive/alimentary MP:0005381 9.95 CASP3 CCND1 CDH1 CDKN2A MAPK9 MYC
6 neoplasm MP:0002006 9.81 AKT1 CCND1 CDH1 CDKN2A MAPK9 MYC
7 reproductive system MP:0005389 9.61 AKT1 BPIFB1 CASP3 CCND1 CDH1 CDKN2A
8 respiratory system MP:0005388 9.28 AKT1 BPIFA1 BPIFB1 CASP3 CCND1 CDKN2A

Drugs & Therapeutics for Nasopharyngeal Disease

Drugs for Nasopharyngeal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 302)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
2
Nimotuzumab Investigational Phase 4,Phase 3,Phase 2 780758-10-3, 828933-61-3
3 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Erythromycin stearate Phase 4
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Erythromycin Estolate Phase 4
7 Erythromycin Ethylsuccinate Phase 4
8 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Cyclooxygenase 2 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
19
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
20
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
21
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
22
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
23
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
24
Hydroxyurea Approved Phase 3,Phase 1 127-07-1 3657
25
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3,Phase 3 128-13-2 31401
26
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
27
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
28
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 154361-50-9 60953
29
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
30
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
31
Sulindac Approved, Investigational Phase 3,Phase 2 38194-50-2 1548887 5352
32
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
33
Budesonide Approved Phase 3,Not Applicable 51333-22-3 63006 5281004
34
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
35
Amifostine Approved, Investigational Phase 3,Phase 2 20537-88-6 2141
36
Epirubicin Approved Phase 3 56420-45-2 41867
37
Oprelvekin Approved, Investigational Phase 3 145941-26-0
38
mometasone furoate Approved, Investigational, Vet_approved Phase 3,Phase 2 83919-23-7
39 Benralizumab Approved, Investigational Phase 3 1044511-01-4
40
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
41
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
42
Acyclovir Approved Phase 3 59277-89-3 2022
43
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
44
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
45
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
46
Calcium Approved, Nutraceutical Phase 3,Phase 2 7440-70-2 271
47
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
48
Ornithine Approved, Nutraceutical Phase 3,Phase 2 3184-13-2, 70-26-8 6262
49 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
50 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 441)
# Name Status NCT ID Phase Drugs
1 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
2 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
3 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
4 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
6 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED) Terminated NCT00140894 Phase 4 MK0966; rofecoxib / Duration of Treatment: 24 weeks;Comparator: placebo / Duration of Treatment: 24 weeks
7 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Unknown status NCT03006588 Phase 2, Phase 3
8 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
9 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
10 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
11 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
12 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Unknown status NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
13 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
14 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
15 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
16 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
17 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
18 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
19 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
20 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
21 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
22 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
23 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
24 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
25 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3 Ursodeoxycholic acid;Placebo
26 Efficacy and Safety of Budesonide Inhalation Suspension for the Treatment of Chronic Rhinosinusitis With Polyposis. Completed NCT03687515 Phase 3 budesonide;budesonide;Prednisone
27 Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety Completed NCT01622569 Phase 3 Fluticasone Propionate
28 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
29 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
30 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis Completed NCT01197612 Phase 3 pulmicort
31 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3 Celecoxib;Ursodeoxycholic acid;Placebo
32 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
33 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
34 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Completed NCT00510692 Phase 2, Phase 3 Eicosapentanoic Acid (EPA);Placebo
35 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
36 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
37 GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT03840421 Phase 3 gemcitabine and cisplatin;cisplatin and fluorouracil;cisplatin
38 Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma Recruiting NCT03837808 Phase 3 Nimotuzumab;Cisplatin
39 Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis Recruiting NCT03806426 Phase 3 Eicosapentaenoic acid free fatty acid (EPA-FFA);Placebo
40 Acute Radiation Oral Mucositis in Nasopharyngeal Carcinoma(NPC) Patients Treated With Combined Radio-Chemotherapy Recruiting NCT03720340 Phase 3 Recombinant Human Interleukin-11;Saline
41 Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Recruiting NCT03707509 Phase 3 Camrelizumab;Placebos;Gemcitabine;Cisplatin
42 GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Recruiting NCT03604965 Phase 3 GP+CCRT;TPF+CCRT
43 Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma Recruiting NCT03601975 Phase 3 Gemcitabine/Cisplatin
44 TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC Recruiting NCT03574324 Phase 3 TPF+CCRT;CCRT+PF
45 Adjuvant PD-1 Antibody in Locoregionally Advanced Nasopharyngeal Carcinoma After Chemoradiotherapy Recruiting NCT03427827 Phase 3 PD-1 antibody
46 Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Recruiting NCT03403829 Phase 3 Gemcitabine
47 Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis Recruiting NCT03401229 Phase 3
48 Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients Recruiting NCT03387774 Phase 3 Cisplatin;Ulinastatin
49 Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC Recruiting NCT03366415 Phase 3 gemcitabine and cisplatin (Induction and adjuvant chemotherapy);gemcitabine and cisplatin (Induction chemotherapy)
50 Mometasone vs Budesonide in CRS With Polyposis Recruiting NCT03323866 Phase 3 Budesonide 0.5 MG/ML;Mometasone nasal spray

Search NIH Clinical Center for Nasopharyngeal Disease

Cochrane evidence based reviews: nasopharyngeal diseases

Genetic Tests for Nasopharyngeal Disease

Anatomical Context for Nasopharyngeal Disease

MalaCards organs/tissues related to Nasopharyngeal Disease:

42
Lung, Liver, Nk Cells, Brain, Colon, Bone, Breast

Publications for Nasopharyngeal Disease

Articles related to Nasopharyngeal Disease:

# Title Authors Year
1
Expression of GRIN2A in benign and malignant nasopharyngeal diseases and its clinical significance. ( 26681223 )
2015
2
Expression and clinical significance of LRRC4 in benign and malignant nasopharyngeal diseases. ( 26662436 )
2015
3
Nasopharyngeal disease in cats: 1. Diagnostic investigation. ( 22511473 )
2012
4
Nasopharyngeal disease in cats: 2. Specific conditions and their management. ( 22511474 )
2012
5
Nasopharyngeal diseases in cats: a retrospective study of 53 cases (1991-1998). ( 10580903 )
1999
6
Management of some benign nasopharyngeal diseases in the adult; supplementary report. ( 13356856 )
1956
7
Surgical treatment of benign nasopharyngeal disease in the adult. ( 14943338 )
1952
8
A new pharyngoscope; facilitating diagnosis and treatment of nasopharyngeal diseases. ( 20994675 )
1946

Variations for Nasopharyngeal Disease

Expression for Nasopharyngeal Disease

Search GEO for disease gene expression data for Nasopharyngeal Disease.

Pathways for Nasopharyngeal Disease

Pathways related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.05 AKT1 CASP3 CDH1 MAPK9 PSMB9 TP53
2
Show member pathways
12.99 AKT1 CASP3 CCND1 CDKN2A MAPK9 MYC
3
Show member pathways
12.84 AKT1 CASP3 CDKN2A MAPK9 MYC TP53
4 12.8 AKT1 CASP3 MAPK9 MYC TP53
5
Show member pathways
12.8 AKT1 CASP3 CCND1 CDH1 CDKN2A MAPK9
6
Show member pathways
12.75 AKT1 CASP3 CDH1 MAPK9 TP53
7
Show member pathways
12.73 AKT1 BRD7 CCND1 CDH1 CDKN2A MYC
8 12.73 AKT1 CASP3 CCND1 CDH1 CDKN2A MAPK9
9
Show member pathways
12.72 AKT1 CCND1 CDH1 CDKN2A MAPK9 TP53
10
Show member pathways
12.66 CASP3 CCND1 MAPK9 MYC PSMB9 SMUG1
11
Show member pathways
12.63 AKT1 CCND1 MAPK9 MYC TP53
12
Show member pathways
12.62 AKT1 CASP3 CCND1 MAPK9 TP53
13
Show member pathways
12.59 AKT1 CCND1 CDKN2A MYC PSMB9 TP53
14 12.57 CASP3 CCND1 CDKN2A MYC TP53
15
Show member pathways
12.53 AKT1 CASP3 CCND1 MAPK9 MYC
16
Show member pathways
12.47 AKT1 CASP3 MAPK9 TP53
17
Show member pathways
12.43 AKT1 CCND1 MYC TP53
18
Show member pathways
12.41 CASP3 CCND1 CDKN2A MYC TP53
19 12.4 AKT1 CCND1 CDKN2A MYC TP53
20 12.4 CCND1 CDH1 CDKN2A MYC TP53
21 12.33 CASP3 CCND1 CDKN2A TP53
22 12.32 AKT1 CASP3 CCND1 MYC TP53
23
Show member pathways
12.3 AKT1 CASP3 MAPK9 PSMB9
24
Show member pathways
12.29 AKT1 CASP3 MAPK9 TP53
25
Show member pathways
12.27 AKT1 CASP3 CCND1 MAPK9 TP53
26
Show member pathways
12.26 CCND1 CDKN2A MAPK9 MYC
27
Show member pathways
12.24 AKT1 CASP3 CCND1 MYC TP53
28 12.19 AKT1 CCND1 CDKN2A MYC TP53
29 12.16 AKT1 CASP3 CCND1 MYC TP53
30
Show member pathways
12.16 AKT1 CASP3 MAPK9 MYC TP53
31 12.1 CDKN2A MAPK9 PSMB9 TP53
32 12.1 AKT1 CCND1 CDH1 MAPK9 MYC PSMB9
33
Show member pathways
12.09 AKT1 CASP3 MAPK9 TP53
34 12.07 CASP3 CCND1 MYC TP53
35 12.07 AKT1 CCND1 MAPK9 MYC TP53
36 12.04 AKT1 CCND1 MYC TP53
37 12.03 AKT1 CCND1 MYC TP53
38 12.02 AKT1 CASP3 CCND1 CDH1 MYC TP53
39 11.95 AKT1 CASP3 CCND1 MAPK9
40 11.94 AKT1 CCND1 CDKN2A MYC TP53
41 11.92 AKT1 CASP3 CCND1 CDH1 MYC TP53
42 11.91 AKT1 MAPK9 MYC
43
Show member pathways
11.91 AKT1 CCND1 CDH1 MAPK9 MYC PSMB9
44 11.9 AKT1 CASP3 MAPK9
45 11.87 CCND1 MYC TP53
46
Show member pathways
11.84 AKT1 CASP3 MAPK9
47
Show member pathways
11.84 AKT1 CASP3 MAPK9
48 11.84 AKT1 CASP3 CCND1 MYC TP53
49 11.83 AKT1 MAPK9 TP53
50 11.82 CCND1 CDH1 MYC

GO Terms for Nasopharyngeal Disease

Cellular components related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 AKT1 ARL2BP BRD7 CASP3 CCND1 CDKN2A
2 nucleoplasm GO:0005654 9.36 AKT1 BRD7 CASP3 CCND1 CDKN2A CFAP45

Biological processes related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.85 AKT1 CDKN2A MAPK9 MYC TP53
2 positive regulation of transcription, DNA-templated GO:0045893 9.85 AKT1 BRD7 CDH1 CDKN2A MYC TP53
3 positive regulation of apoptotic process GO:0043065 9.8 AKT1 CASP3 CDKN2A MAPK9 TP53
4 G1/S transition of mitotic cell cycle GO:0000082 9.72 CCND1 CDKN2A MYC
5 regulation of signal transduction by p53 class mediator GO:1901796 9.69 AKT1 BRD7 TP53
6 striated muscle cell differentiation GO:0051146 9.56 AKT1 CASP3
7 cytokine-mediated signaling pathway GO:0019221 9.55 AKT1 CASP3 CCND1 MYC TP53
8 replicative senescence GO:0090399 9.54 CDKN2A TP53
9 cellular response to organic substance GO:0071310 9.5 CASP3 CCND1 MAPK9
10 cellular response to organic cyclic compound GO:0071407 9.49 AKT1 CASP3
11 mitotic G1 DNA damage checkpoint GO:0031571 9.48 CCND1 TP53
12 cellular response to DNA damage stimulus GO:0006974 9.43 AKT1 CASP3 CCND1 MYC SMUG1 TP53
13 response to UV-A GO:0070141 9.26 AKT1 CCND1
14 positive regulation of mitochondrial membrane potential GO:0010918 9.22 AKT1
15 re-entry into mitotic cell cycle GO:0000320 9.13 CCND1
16 response to organic substance GO:0010033 8.92 AKT1 CASP3 CCND1 CDH1

Molecular functions related to Nasopharyngeal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTPase activating protein binding GO:0032794 9.16 AKT1 CDH1
2 transcription factor binding GO:0008134 9.1 BRD7 CCND1 CDKN2A MAPK9 MYC TP53
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.96 CASP3 CDKN2A

Sources for Nasopharyngeal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....